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Cardiac Function and Heart Failure
1069-107 Hospitalizations in Heart Failure: It's Not What You 
Think
Peter Carson, Christopher M. O'Connor, Alan Miller, Jay N. Cohn, Department of Veterns 
Affairs Medical Center, Washington, DC
Hospitalization for heart failure (HFH) is a major component of morbidity of this disease.
We recently reported that, from the ValHeFT data, HF represented a minority of all hospi-
talization –38% placebo group (J. Card. Failure 9:164; 2003). We have reviewed pub-
lished hospitalization results in the placebo groups of major trials spanning mild-to-
advanced HF to assess the proportion of HF hospitalizations. We also assessed relative
hospitalization rates for HF and all cause(AC) by using published follow-up (FU) (mean in
all studies except CHARM and ATLAS) to estimate exposure time.. 
N= number of randomized patients; EF= ejection fraction; AMR= annual mortality rate: 
FU= follow-up; HFH/Pt/mm= HFH per randomized patient per month
HF is an important cause of hospitalization in HF patients, but are usually a minority of 
events. The proportion of AC hospitalizations that are HF are remarkably constant in 
mild-moderate HF, but increase with advanced HF. AC hospitalizations are also relatively 
constant, although appear to increase with HF severity. In all studies, non HF hospitaliza-
tions, both CV and nonCV, are the dominant component of hospitalization. They require 
further study to determine whether HF therapy can affect this part of the “burden” of heart 
failure.
1069-108 Systolic Heart Failure Is Associated With a Significantly 
Worse Long-Term Survival Than Diastolic Heart Failure 
Among Patients With Coronary Artery Disease
Jeffrey S. Berger, Warren Sherman, Timothy A. Sanborn, David L. Brown, Beth Israel 
Medical Center, New York, NY
Background: Heart failure (HF) in the setting of coronary artery disease (CAD) is asso-
ciated with impaired survival. However, the relative contribution of diastolic (DHF) versus
systolic heart failure (SHF) to the adverse prognosis is unknown. We sought to compare
the impact of diastolic versus systolic dysfunction on survival in patients with HF and
CAD.
Methods: Of 4284 consecutive patients with CAD undergoing PCI at 3 hospitals in New
York City from 1998-1999, 466 patients with previous or current HF and known ejection
fractions (EF) comprised the study population. DHF was defined by an EF > 50% and
SHF by an EF < 50%. All-cause mortality at a mean follow-up of 3 years was the primary
endpoint.
Results: Of the 466 patients with HF, 147 (32%) had DHF. The mean EFs were 56.4 ±
6.8% in the DHF and 37.1 ± 9.1% in the SHF group (P<0.001). Both groups were of sim-
ilar age. DHF patients were more often female (45% vs. 35%, P=0.051). Hypertension,
diabetes, stroke, peripheral vascular disease, renal insufficiency and smoking were simi-
lar in both groups. Patients with DHF were less likely to have a prior myocardial infarction
(8.2% vs. 15.0%, P=0.039). One-vessel CAD was more often associated with DHF (40%
vs. 27%, P=0.003) whereas 3-vessel CAD was more common in SHF patients (32% vs.
23%, P=0.044). Stents were placed in approximately 75% of patients in both groups and
GP IIb/IIIa receptor inhibitors were administered to 25% of patients in each group. Angio-
graphic success was 97% in both groups. In-hospital mortality was 1.4% and 3.8% in the
DHF and SHF population, respectively (P=0.158). The 3-year mortality was greater in
patients with SHF than in those with DHF (30% vs. 10%, P<0.001). On Cox proportional
hazards analysis SHF was associated with a significant independent increase in the haz-
ard of late mortality (Hazard Ratio, 4.80, 95% Confidence Interval, 2.38-9.68, P<0.001).
Conclusion: Patients with CAD and SHF have an approximately 5-fold increase in the
hazard of late mortality following PCI compared to those with CAD and DHF. These find-
ings suggest that the optimum treatment for patients with SHF following PCI is not known
and may require greater integration of revascularization and implantable defibrillator
strategies.
1069-109 Individualized Prediction of Heart Failure Survival: An 
Analysis From PRAISE1
Wayne C. Levy, Dariush Mozaffarian, Regina G. Nye, Anne Cropp, University of 
Washington, Seattle, WA, Pfizer, Groton, CT
Previous heart failure (HF) risk models stratify patients into 3 risk groups using peak oxy-
gen consumption (VO2). An individualized estimate of survival in HF has not been
reported. We retrospectively investigated predictors of survival among 1,125 HF patients
in PRAISE1 (NYHA 3B-4, EF<30%, ACEI, digoxin, diuretics, 403 deaths). A stepwise
Cox proportional hazard model was used to identify multivariate predictors of risk; the
final model included age, gender, ischemic etiology, NYHA class, ejection fraction, sys-
tolic blood pressure, K-sparing diuretic use, statin use, allopurinol use, hemoglobin, %
lymphocyte count, uric acid, sodium, cholesterol, and diuretic dose/kg. Using this model,
the predicted survival for individual patients was compared to the actual survival (mean
1-year predicted survival = 74% ± 17%, Range 3%-97%). The lowest risk decile had an
estimated 1- and 2-year survival of 92% and 84%, respectively, and the actual survival
was 95% and 82%. The highest risk decile had an estimated 1- and 2-year survival of
36% and 13%, respectively, and the actual survival was 30% and 16%. The hazard ratio
for the highest risk decile was 12-fold greater than for the lowest risk decile.
We have developed an individualized estimation of survival in HF using easily obtained
clinical and laboratory values without measurement of peak VO2. We are attempting to
validate the model in other large heart failure cohorts and to add ACEIs, ARBs, B-block-
ers, and devices to the model.
1069-110 Predictors of Mortality in 1,346 Patients With Heart 
Failure Scheduled for Guideline-Based Treatment
Heinz Voeller, Clemens Dovifat, Bettina Ehrlich, Simone Schulz, Kirsten Stolze, Wolfgang 
Kamke, Karl Wegscheider, Klinik am See, Rüdersdorf, Germany, Institut for Statistics and 
Econometry, Hamburg, Germany
The prognosis of patients (P) with heart failure has been shown to improve in controlled
studies with ACE inhibitors and/or beta blockers. The extent to which treatment guide-
lines isussed by professional organisations are implentable in daily clinical practice is
unknown, as are the effects on prognosis and mortality predictors.
Methods:
1346 consecutive patients (64 ±10 years, 27% women) with an ejection fraction (EF) <
45% (mean EF 36.3±6%) were enrolled in the study (between 01/98 and 12/00). The eti-
ology of the cardiomyopathy was ischemic in 77%, valvular in 6.5% and due to other
causes in 16.5% of the cases. 15.5% of the patients had atrial fibrillation. During inpatient
rehabilitation resting ECG, exercise testing, Holter monitoring with heart rate (HR) vari-
ability, echocardiogram to determine LV diameter, LV filling (E/A), mitral insufficiency and
pulmonary hypertension, and a 6-minute walk-test were performed. The drug therapy
was noted at the time of discharge. The patients were followed for 731 days.
Results:
89%/10 % of the patients received ACE inhibitors/AT1-blockers, 82 % beta blockers, 8 %
amiodarone, 57 % diuretics , and 35 % digitalis. Overall mortality was 11 %, cardiac mor-
tality was 6 %. Significant differences were observed in sinus rhythm (85.3 % survivors
vs. 68.4 % nonsurvivors), number of VES/h (140 vs. 205), heart rate variability (SDANN
71.2 vs. 65.7), systolic diameter on 2 D-echo (LVSD 47.7 vs. 51.5 mm), E/A in the trans-
mitral flow pattern (1.46 vs. 1.79), maximum exercise capacity (76.3 W vs. 57.9 W) and
6-minute walk test (375 m vs. 302 m). Statins and BMI (kg/m2) did not differ. Multivariate
analysis showed that age, pulmonal hypertension, atrial fibrillation, mitral insufficieny,
higher NYHA grade, necessity of diuretics and digitalis, a short distance in the 6-minute
walk test and low exercise capacity were associated with a significantly higher mortality.
Conclusion:
Guideline-based therapy could be established in approximately 90 % of patients with
heart failure and was associated with improved prognosis. While physical fitness was
beneficial for the prognosis, symptomatic therapy was related to poorer outcome.
1069-111 Depression Predicts Mortality and Hospitalization in 
Patients With Acute Myocardial Infarction Complicated 
by Heart Failure: Data From the EPHESUS Trial
John S. Rumsfeld, Philip Jones, Mary A. Whooley, Mark D. Sullivan, Bertram Pitt, William 
S. Weintraub, John A. Spertus, Denver VA Medical Center, Denver, CO, University of 
Missouri-Kansas City, Kansas City, MO
Background: We evaluated depression as a predictor of all-cause mortality and cardio-
vascular mortality or hospitalization in patients with acute myocardial infarction compli-
cated by heart failure.
Methods: In addition to clinical data, patients in the EPHESUS trail (NEJM
2003;102:2700-2706) completed a Medical Outcomes Study-Depression (MOS-D) ques-
tionnaire at baseline. Mean follow-up was 16 months. Primary outcomes were a) all-
cause mortality; and b) cardiovascular death or hospitalization. Kaplan-Meier curves
were used to examine the unadjusted relationship between depression and outcomes.
Cox proportional hazards regression was used to assess the relationship between
depression and outcomes, adjusting for baseline clinical variables.
Results: 143/634 patients (22.6%) had significant depressive symptoms at baseline
(MOS-D score >0.06). In unadjusted analysis, depression was significantly associated
with both all-cause mortality and cardiovascular death or hospitalization (Figure). After
risk adjustment, depression remained associated with all-cause mortality (HR 1.75; 95%
CI 1.15-2.68; p=0.01) and cardiovascular death or hospitalization (HR 1.39; 95% CI 1.02-
N EF
%
AMR
%
FU HFH HFH
%
HFH/PT/mo AC Hosp H/PT/mo
CHARM-Preserved 1509 54 5.2 36.6 566 22.2 0.07 2545 0.046
CHARM-ACEI Intol 1015 30 10.9 33.7 608 33 0.017 1835 0.053
CHARM-added 1272 28 9.4 41 836 30 0.016 2798 0.053
SOLVD Tx 1284 24.8 11.6 41 971 34 0.018 2833 0.053
ATLAS 1596 24 11.7 46 1576 35 0.02 4397 0.06
MERIT 2001 28 10.0 12 451 39 0.018 1149 0.047
DIG 3403 28 11.3 37 2553 37 0.02 6277 0.053
VALHEFT 2499 27 9.5 23 1189 38 0.02 3106 0.054
COPERNICUS 1133 20 16.7 10.4 441 53 0.037 827 0.07
VEST 1277 21 24.1 9.5 614 48 0.050 1260 0.10
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1.91; p=0.04).
Conclusion: Depression is associated with all-cause mortality and cardiovascular death
or hospitalization following acute MI complicated by heart failure. Studies are warranted
to evaluate whether a depression intervention can improve survival and/or reduce hospi-
talization for these patients.
1069-112 Mortality of Heart Failure Patients From the General 
Population: Effects of the Therapeutic Regimen
Mauro Di Bari, Giorgia Valpiani, Mirko Di Martino, Pierangelo Geppetti, Giulio Masotti, 
Ezio Degli Esposti, University of Florence, Florence, Italy, CliCon Srl Health, Economics 
and Outcomes Research, Ravenna, Italy
BACKGROUND
Randomized clinical trial (RCT) have shown that ACE-inhibitors (ACE-I) and β-blockers
(βB) improve survival in patients with heart failure (HF) with additive effect. Whether
these therapeutic benefits are maintained in HF patients of the “real word” is debated.
This study compared survival of HF patients from the general population as a function of
cardiovascular (CV) drug use.
METHODS
All hospital admissions, drug prescriptions (National Health Service Drug Prescription
Database), and mortality data of the entire population (approximately 360,000) residing
in the health district of Ravenna, Italy have been recorded since 1996. Patients dis-
charged from hospital with a first diagnosis of HF (ICD 9 code 428) from 01.01.1997 to
12.31.1999 were selected from this database and followed up for one year. Patients were
grouped into 5 cohorts according to drug prescription during the follow-up: diuretics (D)
alone, ACE-I alone, D+ACE-I, D+ACE-I+βB, and other drugs. Mortality rates were com-
puted using a person-years denominator. Cox’s model was used to compute mortality
hazard ratio (HR) and 95% confidence interval (95% CI), adjusting for age, sex, history
of: diabetes, hypertension, heart disease and previous CV events (myocardial infarction,
coronary artery disease, stroke, and transient ischemic attack).
RESULTS
2,441 HF patients (mean age 78 ± 10 years; females 53.7%) were included. Of them,
20.2% were on D, 7.2% on ACE-I, 56.2% on D+ACE-I, 5.4% on D+ACE-I+βB, and 11.0%
on other drugs. Crude cumulative mortality was 36.8%, 26.7%, 20.8%, 3.9% and 34.1
respectively (p<0.001). Compared to patients receiving D+ACE-I+βB, the risk of death
increased significantly in those on other regimens, with adjusted HRs (95% CIs) of 3.9
(1.6-9.4), 5.5 (2.2-14.0), 6.3 (2.6-15.6), 6.5 (2.6-16.1) in those on D+ACE-I, ACE-I, D or
other drugs, respectively.
CONCLUSION
In this large cohort of HF patients from the general population, a therapeutic regimen
based on the association D+ACE–I+βB was associated with the lowest mortality. Survival
decreased progressively in participants on D+ACE-I, ACE-I, D, and other drugs. These
results from a non-experimental setting strongly support those obtained from RCT.
1069-113 Cause of Death Across Full Spectrum of Ventricular 
Function in Patients With Heart Failure: The CHARM 
Study
Scott Solomon, Bertil Olofsson, Peter Finn, Hicham Skali, Leonardo Zornoff, Satish 
Kenchaiah, Nagesh Anavekar, Jan Ostergren, Eric Michelson, Uche Sampson, Pratima 
Anavekar, Salim Yusuf, John McMurray, Chris Granger, Marc Pfeffer, Brigham and 
Women's Hospital, Boston, MA
Background: While the incidence and causes of death in heart failure (HF) patients with
reduced left ventricular (LV) systolic function have been previously reported, these have
not been described in patients with preserved systolic function. Methods: The Cande-
sartan in Heart Failure (CHARM) trial enrolled 7601 patients with symptomatic heart fail-
ure, and EF ranging from 5% to 91%. Cause of death was classified by an independent
review committee. The annualized incidence of death was calculated in each quintile
(median follow-up 38 mos). Results: All-cause and CV death declined with each increas-
ing quintile of ejection fraction, whereas non-CV death was similar across quintiles. The
proportion of non-CV death increased in the highest quintile of EF. Sudden death and
fatal HF accounted for the majority of CV death and the proportion of death attributable to
sudden death or HF decreased with EF. The annual incidence of fatal MI was low (<1% in
all groups). The proportion of deaths attributable to MI or stroke was similar across quin-
tiles. Conclusion: In HF patients with a broad range of ejection fractions, death attrib-
uted to sudden death and HF accounted for the majority of the cardiovascular death,
although in decreasing absolute number and proportion with increasing EF. These find-
ings have important implications for the choice of end-points in trials in patients with heart
failure and preserved LV systolic function. 
1069-114 Impact of Renal Insufficiency and Chronic Diuretic 
Therapy on Outcome and Resource Utilization in 
Patients With Acute Decompensated Heart Failure
Maria Rosa Costanzo, J. Thomas Heywood, Teresa DeMarco, Gregg C. Fonarow, Janet 
S. Wynne, Midwest Heart Specialists; Edward Hospital, Naperville, IL
Background: There is a paucity of information on renal insufficiency (RI) in patients (pts)
with heart failure (HF) due to exclusion of RI pts from HF clinical trials. Methods: Data
from 46,599 hospitalizations (Apr, 2003) for decompensated HF were collected in the
ADHERETM Registry. Of 35,423 pts with Cr < 2.0 mg/dl, 10,648 (30%) did not receive
chronic diuretics (ChD) (A) and 24,775 (70%) did (B). Of 10,317 pts with Cr > 2.0 mg/dl,
2,937 (28%) did not receive ChD (C) and 7,380 (72%) did (D). Resource utilization and
outcomes were compared in the 4 groups (Chi square and ANOVA). Results: There was
a stepwise increase in in-hospital mortality with the lowest rate occurring in A and the
highest in D. In pts with low and high Cr, use of ChD was associated with the highest
mortality rate. A stepwise decrease in the percentage of cases who were completely
asymptomatic at discharge, with the highest percentage in A and the lowest percentage
in D, was observed. Use of ChD was associated with fewer asymptomatic discharges in
pts with low and high Cr, (46% vs. 52% and 39% vs. 45%; both P < 0.0001). There was a
stepwise increase in hospital length of stay (LOS) with the shortest in A and the longest
in D. In pts with low and high Cr ChD were associated with longer LOS (5.5 ± 4.9 vs. 5.8
± 6.1 days, P<0.0001 and 6.1± 5.8 vs. 6.9 ± 6.1 days, P< 0.0001). Conclusions: RI
worsens patient outcomes in terms of resource utilization, symptom status and survival.
ChD were associated with poorer outcomes and greater resource utilization in pts with
and without RI.
1069-115 Prognostic Significance of Deteriorating Renal Function 
in Patients With Decompensated Heart Failure
Doron Aronson, Darlane P. Horton, Andrew J. Burger, Rambam Medical Center, Haifa, 
Israel, Beth Israel Deaconess Medical Center, Boston, MA
Introduction: Renal dysfunction frequently accompanies heart failure progression, and
deterioration of renal function in patients (pts) admitted with decompensated CHF is
common. However, the prognostic significance of worsening renal function in this setting
is not known.
Methods: We studied the relation between deterioration of renal function and 6-month
mortality in 498 pts admitted with decompensated CHF. Deterioration of renal function
was defined as an increase of > 0.5 mg/dL in creatinine level within 14 days from admis-
sion.
Results: At 14-days, 103 pts (21%) had evidence of deteriorating renal function. During
a 6-month follow-up, 112 pts (22%) died. Kaplan-Meier analysis is shown in the Figure. A
Cox proportional-hazards model, adjusted for age, gender, diabetes, etiology of CHF,
baseline creatinine, baseline heart rate, EF, atrial fibrillation, and medications (ACE inhib-
itors, β-blockers, digoxin, or amiodarone use), showed that deteriorating renal function
was a strong independent predictor of 6-month mortality (RR = 2.93, 95% CI 1.81-4.72, p
< 0.0001). Baseline creatinine was also an independent predictor of 6-month mortality
(RR = 1.20 for every 1.0 mg/dL increase, 95% CI 1.06-1.36, p = 0.003), but was not pre-
dictive of deteriorating renal function.
Conclusion: In pts admitted for heart failure decompensation, evidence of deteriorating
renal function is a powerful independent predictor of short-term mortality. 
